Company intelligence / Profile preview

CroiValve

Ownership: Private
Development stage: Phase 1

Overview

CroiValve has developed the DUO™ Tricuspid Coaptation Valve System, a minimally invasive transcatheter device designed to treat severe tricuspid regurgitation. The system combines repair and replacement elements to address unique challenges of the tricuspid valve. The company has received FDA Investigational Device Exemption and CMS approval for an Early Feasibility Study in the US. Initial results from studies such as TANDEM I have been positive, supporting further development toward broader clinical trials and commercialization.

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapyTranscatheter valve system
Industry: Implantable Medical Devices

Partnerships

None specifically disclosed; investors include several venture funds which may provide strategic support.

Beyond the preview

Go deeper on CroiValve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CroiValve.

Explore the full profile